2-(3-Propan-2-yl-1,2-oxazol-5-yl)acetic acid | 1024606-08-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(3-Propan-2-yl-1,2-oxazol-5-yl)acetic acid
• CAS: 1024606-08-3
• 化学式: C₈H₁₁NO₃
• 分子量: 169.18
• InChiKey: WTVQJIVEVKJGTP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  63.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(3-Propan-2-yl-1,2-oxazol-5-yl)acetic acid 、 2-氨基-5-氯二苯甲酮 在 三氯氧磷 作用下， 生成 5-(2,6-Dichloro-4-phenylquinolin-3-yl)-3-propan-2-yl-1,2-oxazole
  参考文献：
  名称：

  Synthesis and evaluation of novel 3,4,6-substituted 2-quinolones as FMS kinase inhibitors

  摘要：

  A series of 3,4,6-substituted 2-quinolones has been synthesized and evaluated as inhibitors of the kinase domain of macrophage colony-stimulating factor-1 receptor (FMS). The fully optimized compound, 4-(4-ethyl-phenyl)-3-(2-methyl-3H-imidazol-4yl)-2-quinolone-6-carbonitrile 21b, has an IC50 of 2.5 nM in an in vitro assay and 5.0 nM in a bone marrow-derived macrophage cellular assay. Inhibition of FMS signaling in vivo was also demonstrated in a mouse pharmacodynamic model. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.01.088

文献信息

• SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS
  申请人：Das Jagabandhu

  公开号：US20130158001A1

  公开（公告）日：2013-06-20

  Disclosed are compounds of Formula (I): (I) or stereoisomers, salts, or prodrugs thereof, wherein: (i) R1 and R2 are independently C 1 -C 4 alkyl, or (ii) R 1 and R 2 together with the carbon atom to which they are attached, form a cyclic group; and Q is H, C 1-6 alkyl, phenyl or 5- to 6-membered heteroaryl substituted with zero to 3 substituents, and G is defined herein. Also disclosed are method of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. There compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and chronic inflammatory disease.

  本发明涉及式(I)的化合物：(I)或其立体异构体、盐或前药，其中：(i) R1和R2独立地是C1-C4烷基，或者(ii) R1和R2与它们连接的碳原子一起形成一个环状基团；Q为H、C1-6烷基、苯基或5-到6-成员杂环芳基取代零至3个取代基，G在此定义。还公开了使用这些化合物作为选择性G蛋白偶联受体S1P1激动剂的方法，以及包含这些化合物的制药组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或疾病中是有用的，例如自身免疫性疾病和慢性炎症性疾病。
• US8178681B2
  申请人：——

  公开号：US8178681B2

  公开（公告）日：2012-05-15
• US8367666B2
  申请人：——

  公开号：US8367666B2

  公开（公告）日：2013-02-05
• US8822510B2
  申请人：——

  公开号：US8822510B2

  公开（公告）日：2014-09-02
• Synthesis and evaluation of novel 3,4,6-substituted 2-quinolones as FMS kinase inhibitors
  作者：Mark J. Wall、Jinsheng Chen、Sanath Meegalla、Shelley K. Ballentine、Kenneth J. Wilson、Renee L. DesJarlais、Carsten Schubert、Margery A. Chaikin、Carl Crysler、Ioanna P. Petrounia、Robert R. Donatelli、Edward J. Yurkow、Lisa Boczon、Marie Mazzulla、Mark R. Player、Raymond J. Patch、Carl L. Manthey、Christopher Molloy、Bruce Tomczuk、Carl R. Illig

  DOI：10.1016/j.bmcl.2008.01.088

  日期：2008.3

  A series of 3,4,6-substituted 2-quinolones has been synthesized and evaluated as inhibitors of the kinase domain of macrophage colony-stimulating factor-1 receptor (FMS). The fully optimized compound, 4-(4-ethyl-phenyl)-3-(2-methyl-3H-imidazol-4yl)-2-quinolone-6-carbonitrile 21b, has an IC50 of 2.5 nM in an in vitro assay and 5.0 nM in a bone marrow-derived macrophage cellular assay. Inhibition of FMS signaling in vivo was also demonstrated in a mouse pharmacodynamic model. (c) 2008 Elsevier Ltd. All rights reserved.